Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, proliferation and metastasis in several cancer types.
1. A method of inhibiting or reducing tumor cell detachment, proliferation and/or metastasis comprising:
administering to a subject in need thereof an effective amount of an Oncostatin M (OSM) antagonist, wherein reducing tumor cell detachment, proliferation and/or metastasis comprises reducing size or number of lung metastases; and wherein expression or activity of OSM is reduced, and wherein said OSM antagonist is one or more of OSM-SMI-8, OSM-SMI-10, or OSM-SMI-11.
2. The method of claim 1 , wherein the OSM antagonist inhibits or reduces the spread of a primary tumor to a pre-metastatic organ of the subject.
3. The method of claim 1 further comprising administering to the subject an effective amount of gp-130 antagonist.
4. The method of claim 1 , wherein said small molecule is OSM-SMI-8.
5. The method of claim 1 , further comprising administering to the subject an effective amount of an anti-OSM antibody or a fragment thereof.